Kura Oncology and Caspian outline diabetes drug development plan

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. NDAQ
9. TSCO
10. BE

Go back to Kura Oncology and Caspian outline diabetes drug development plan

Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes

October 13, 2026 7:30 AM EDT

EASD findings support clinical evaluation of a next-generation oral menin inhibitor designed to restore insulin-producing capacity

IND-enabling development underway to support Phase 1 clinical proof-of-concept study to assess safety and endogenous insulin production

Investor webcast today, October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT

SAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Caspian Therapeutics, Inc. (Caspian) and Kura Oncology, Inc. (Nasdaq: KURA, Kura) plan to outline the development strategy for KO-7246, Caspians selective, oral menin inhibitor designed for diabetes and other chronic metabolic diseases, in a webcast later today. Management from both... More